The test results will be available in three to five days after the blood sample is collected and sent to the lab. Credit: fernando zhiminaicela / Pixabay.

Circular Genomics has introduced MindLight, a test designed to predict the response of patients with depression to selective serotonin reuptake inhibitor (SSRI) antidepressant treatment.

This new SSRI antidepressant response test is the first to utilise circular RNA biomarkers, aiming to enhance precision psychiatry and set new standards in mental health care.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The MindLight test offers significant benefits for medication management in depression treatment. Current data indicates that only 41% of patients respond to SSRIs, leaving the majority to seek alternative therapies.

Its ability to identify patients’ likelihood of responding to SSRIs could streamline the treatment process.

The test demonstrated a prognostic accuracy of 77%, a considerable improvement over the standard first-line therapy response rates of 40%-50% in clinical trials involving SSRIs.

According to the data, patients classified as having a “High Likelihood of Response” by the test are 3.4 times more likely to respond to SSRIs than those deemed to have a “Low Likelihood of Response”.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Circular Genomics CEO Paul Sargeant said: “The current standard of care for depression treatment relies on a process of educated guessing, which can lead to delays in managing the condition effectively.

“SSRIs are the most widely prescribed antidepressant medications, yet less than half of patients achieve clinical response from those drugs.

“The MindLight antidepressant response test can help doctors determine if SSRI medication will be beneficial, and patients can start a personalised and effective treatment plan in as little as one week.”

MindLight is accessible to patients through their physicians or licensed healthcare providers. After a blood sample is collected and sent to a laboratory, the analysis is completed within three to five days.

The results are then provided to the ordering physician in a format that is both easy to understand and clinically actionable.